Vaccination and passive immunisation against Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 1, 2008, Pages

  Schaffer, Adam C ^a   Lee, Jean C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Active immunisation; Passive immunotherapy; Staphylococcus aureus; Vaccine

Indexed keywords

ADHESIN; ALPHA HEMOLYSIN; AUROGRAB; BSYX A110; ETI 211; IMMUNOGLOBULIN G; INH A21; N ACETYLGLUCOSAMINE; PAGIBAXIMAB; PLACEBO; POLY N ACETYLGLUCOSAMINE; POLYCLONAL ANTIBODY; PSEUDOMONIC ACID; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; V710; VANCOMYCIN; VERONATE; VIRULENCE FACTOR;

ACTIVE IMMUNIZATION; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 53849102169     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.009     Document Type: Article

References (35)

1. Fattom A., Schneerson R., Szu S.C., Vann W.F., Shiloach J., Karakawa W.W., et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 58 (1990) 2367-2374
2. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346 (2002) 491-496
3. O'Riordan K., and Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 17 (2004) 218-234
4. Cocchiaro J.L., Gomez M.I., Risley A., Solinga R., Sordelli D.O., and Lee J.C. Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Mol Microbiol 59 (2006) 948-960
5. Pohlmann-Dietze P., Ulrich M., Kiser K.B., Doring G., Lee J.C., Fournier J.M., et al. Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Infect Immun 68 (2000) 4865-4871
6. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C., et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99 (2002) 6573-6578
7. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74 (2006) 2215-2223
8. Josefsson E., Hartford O., O'Brien L., Patti J.M., and Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184 (2001) 1572-1580
9. Vernachio J., Bayer A.S., Le T., Chai Y.L., Prater B., Schneider A., et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 47 (2003) 3400-3406
10. Vernachio J.H., Bayer A.S., Ames B., Bryant D., Prater B.D., Syribeys P.J., et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50 (2006) 511-518
11. Bloom B., Schelonka R., Kueser T., Walker W., Jung E., Kaufman D., et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 24 (2005) 858-866
12. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151 (2007) 260-265
13. Hall A.E., Domanski P.J., Patel P.R., Vernachio J.H., Syribeys P.J., Gorovits E.L., et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71 (2003) 6864-6870
14. Patti J.M. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22 Suppl. 1 (2004) S39-S43
15. Weems Jr. J.J., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P., et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 2751-2755
16. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 26 (2006) 290-295
17. Rupp M.E., Holley Jr. H.P., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P., et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51 (2007) 4249-4254
18. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C., et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 68 (2000) 3200-3209
19. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110 (2002) 285-291
20. Weisman L.E. Antibody for the prevention of neonatal nosocomial staphylococcal infection: a review of the literature. Arch Pediatr 14 Suppl. 1 (2007) S31-S34
21. Kelly-Quintos C., Kropec A., Briggs S., Ordonez C.L., Goldmann D.A., Pier G.B., et al. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 192 (2005) 2012-2019
22. Maira-Litran T., Kropec A., Goldmann D.A., Pier G.B., Maira-Litran T., Kropec A., et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 73 (2005) 6752-6762
23. Stranger-Jones Y.K., Bae T., and Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 103 (2006) 16942-16947
24. Mazmanian S.K., Skaar E.P., Gaspar A.H., Humayun M., Gornicki P., Jelenska J., et al. Passage of heme-iron across the envelope of Staphylococcus aureus. Science 299 (2003) 906-909
25. Adlam C., Ward P.D., McCartney A.C., Arbuthnott J.P., and Thorley C.M. Effect immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits. Infect Immun 17 (1977) 250-256
26. Hume E.B., Dajcs J.J., Moreau J.M., and O'Callaghan R.J. Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect Immun 68 (2000) 6052-6055
27. Menzies B.E., and Kernodle D.S. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 64 (1996) 1839-1841
28. Wardenburg J.B., and Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205 (2008) 287-294
29. Lowell G.H., Colleton C., Frost D., Kaminski R.W., Hughes M., Hatch J., et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun 64 (1996) 4686-4693
30. LeClaire R.D., Hunt R.E., Bavari S., LeClaire R.D., Hunt R.E., and Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 70 (2002) 2278-2281
31. Park J., Jagasia R., Kaufmann G.F., Mathison J.C., Ruiz D.I., Moss J.A., et al. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14 (2007) 1119-1127
32. Weidenmaier C., Kokai-Kun J.F., Kristian S.A., Chanturiya T., Kalbacher H., Gross M., et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 10 (2004) 243-245
33. Schaffer A.C., Solinga R.M., Cocchiaro J., Portoles M., Kiser K.B., Risley A., et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 74 (2006) 2145-2153
34. Clarke S.R., Brummell K.J., Horsburgh M.J., McDowell P.W., Mohamad S.A.S., Stapleton M.R., et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193 (2006) 1098-1108
35. Risley A.L., Loughman A., Cywes-Bentley C., Foster T.J., and Lee J.C. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J Infect Dis 196 (2007) 919-927